PE20210660A1 - Inhibidores de canal de potencial de receptor transitorio de oxadiazol - Google Patents
Inhibidores de canal de potencial de receptor transitorio de oxadiazolInfo
- Publication number
- PE20210660A1 PE20210660A1 PE2020001418A PE2020001418A PE20210660A1 PE 20210660 A1 PE20210660 A1 PE 20210660A1 PE 2020001418 A PE2020001418 A PE 2020001418A PE 2020001418 A PE2020001418 A PE 2020001418A PE 20210660 A1 PE20210660 A1 PE 20210660A1
- Authority
- PE
- Peru
- Prior art keywords
- substituted
- methyl
- oxadiazole
- transient
- channel inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 title 1
- 230000001052 transient effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 abstract 1
- UGLQOTZNBCEHHB-GXTWGEPZSA-N 1-[[3-[(3R,5R)-5-(4-chlorophenyl)oxolan-3-yl]-1,2,4-oxadiazol-5-yl]methyl]-7-methylpurin-6-one Chemical compound ClC1=CC=C(C=C1)[C@H]1C[C@@H](CO1)C1=NOC(=N1)CN1C=NC=2N=CN(C=2C1=O)C UGLQOTZNBCEHHB-GXTWGEPZSA-N 0.000 abstract 1
- KVSPYEYQFMGJNK-GXTWGEPZSA-N 1-[[3-[(3R,5R)-5-(4-fluorophenyl)oxolan-3-yl]-1,2,4-oxadiazol-5-yl]methyl]-7-methylpurin-6-one Chemical compound FC1=CC=C(C=C1)[C@H]1C[C@@H](CO1)C1=NOC(=N1)CN1C=NC=2N=CN(C=2C1=O)C KVSPYEYQFMGJNK-GXTWGEPZSA-N 0.000 abstract 1
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 abstract 1
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Ink Jet (AREA)
- Pyrrole Compounds (AREA)
- Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
Abstract
Referido a compuestos derivados de 1,2,4-oxadiazol de formula general (I); donde A es heteroarilo biciclico fusionado 6-6 sustituido o no; heteroarilo biciclico fusionado 5-6 sustituido o no; X es un enlace, alquilenoC1-4, -O-, ente otros; R1 es: H o alquilo C1-6; R4 es fenilo sustituido o no; heteroarilo sustituido o no, o naftilo sustituido o no, o R1 y R4 pueden formar juntos un cicloalquilo C3-6 fusionado con un fenilo, entre otros; n es: 0 a 3. Un compuesto seleccionado es 1-((3-((3R,5R)-5-(4-clorofenil)tetrahidrofuran-3-il)-1,2,4-oxadiazol-5-il)metil)-7-metil-1,7-dihidro-6H-purin-6-ona, 1-((3-((3R,5R)-5-(4-fluorofenil)tetrahidrofuran-3-il)-1,2,4-oxadiazol-5-il)metil)-7-metil-1H-purin-6(7H)-ona. Dichos compuestos son antagonistas de canal cationico de potencial de receptor transitorio (TRPA1). Tambien refiere a un metodo de preparacion y una composicion farmaceutica que comprende dicho compuesto, siendo util en el tratamiento de enfermedades y condiciones mediadas por TRPA1, tales como dolor.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862644987P | 2018-03-19 | 2018-03-19 | |
US201862676057P | 2018-05-24 | 2018-05-24 | |
US201862725488P | 2018-08-31 | 2018-08-31 | |
US201962812806P | 2019-03-01 | 2019-03-01 | |
PCT/US2019/022659 WO2019182925A1 (en) | 2018-03-19 | 2019-03-18 | Oxadiazole transient receptor potential channel inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210660A1 true PE20210660A1 (es) | 2021-03-31 |
Family
ID=65952221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020001418A PE20210660A1 (es) | 2018-03-19 | 2019-03-18 | Inhibidores de canal de potencial de receptor transitorio de oxadiazol |
Country Status (19)
Country | Link |
---|---|
US (3) | US10710994B2 (es) |
EP (1) | EP3768260A1 (es) |
JP (2) | JP7095106B2 (es) |
KR (2) | KR20230070333A (es) |
CN (1) | CN111867585A (es) |
AU (1) | AU2019237992A1 (es) |
BR (1) | BR112020018983A2 (es) |
CA (1) | CA3091486A1 (es) |
CL (1) | CL2020002399A1 (es) |
CO (1) | CO2020011852A2 (es) |
CR (1) | CR20200413A (es) |
IL (2) | IL276654B2 (es) |
MA (1) | MA52077A (es) |
MX (1) | MX2020009657A (es) |
PE (1) | PE20210660A1 (es) |
PH (1) | PH12020551501A1 (es) |
SG (1) | SG11202009136RA (es) |
TW (1) | TWI829676B (es) |
WO (1) | WO2019182925A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10710994B2 (en) * | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス, インコーポレイテッド | 心臓サルコメア阻害剤 |
TW202023648A (zh) | 2018-08-31 | 2020-07-01 | 美商胞質動力學公司 | 心臟肌小節抑制劑 |
BR112021000209A2 (pt) | 2018-08-31 | 2021-08-24 | Xenon Pharmaceuticals Inc. | Compostos de sulfonamida substituída por heteroarila e seu uso como agentes terapêuticos |
WO2021233752A1 (en) | 2020-05-19 | 2021-11-25 | Bayer Aktiengesellschaft | Trpa1 antagonists for the treatment of diseases associated with pain and inflammation |
FR3114235A1 (fr) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer |
US11919909B2 (en) | 2021-03-04 | 2024-03-05 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
WO2023164679A1 (en) | 2022-02-28 | 2023-08-31 | Genentech, Inc. | Processes for the preparation of phenyltetrahydrofuran compounds |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
IL96891A0 (en) | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
EP0652775B1 (en) | 1992-07-27 | 2000-04-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Targeting of liposomes to the blood-brain barrier |
EP1277744A4 (en) * | 2000-04-21 | 2007-07-11 | Shionogi & Co | OXADIAZONE DERIVATIVES WITH ANTIBODY EFFECT |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
EP1554572B1 (en) | 2001-07-25 | 2009-10-14 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
JP4350517B2 (ja) | 2001-11-09 | 2009-10-21 | シーブイ・セラピューティクス・インコーポレイテッド | A2bアデノシン受容体アンタゴニスト |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
WO2004050062A2 (en) | 2002-12-03 | 2004-06-17 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
US20050089473A1 (en) | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
WO2008119741A2 (en) | 2007-03-29 | 2008-10-09 | Novartis Ag | 3-imidazolyl-indoles for the treatment of proliferative diseases |
CN101801362B (zh) | 2007-06-22 | 2014-01-22 | 海德拉生物科学公司 | 用于治疗病症的方法和组合物 |
US20120046305A1 (en) | 2008-09-24 | 2012-02-23 | Moran Magdalene M | Methods and compositions for treating respiratory disorders |
AU2010227245B2 (en) | 2009-03-23 | 2015-09-10 | Glenmark Pharmaceuticals S.A. | Fused pyrimidine-dione derivatives as TRPA1 modulators |
WO2010125469A1 (en) | 2009-04-29 | 2010-11-04 | Glenmark Pharmaceuticals, S.A. | Pyrimidinedione-fused heterocyclic compounds as trpa1 modulators |
WO2011114184A1 (en) | 2010-03-15 | 2011-09-22 | Glenmark Pharmaceuticals S.A. | Amides of heterocyclic compounds as trpa1 inhibitors |
WO2011132017A1 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Pyrido[3,4-d]pyrimidinyl acetamide derivatives as trpa1 modulators |
EA023141B1 (ru) | 2010-12-20 | 2016-04-29 | Гленмарк Фармасьютикалс С.А. | Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1 |
JP6182072B2 (ja) | 2012-01-17 | 2017-08-16 | Eaファーマ株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
KR101939657B1 (ko) | 2013-02-20 | 2019-01-17 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물 |
WO2015155306A1 (en) | 2014-04-11 | 2015-10-15 | Almirall, S.A. | New trpa1 antagonists |
BR112017017052A2 (pt) | 2015-02-15 | 2018-04-10 | F. Hoffmann-La Roche Ag | derivados de 1-(het)arilsulfonil-(pirrolidina ou piperidina)-2-carboxamida e seu uso como antagonistas de trpa1 |
WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
EP3544979B1 (en) | 2016-11-28 | 2021-08-04 | F. Hoffmann-La Roche AG | Oxadiazolones as transient receptor potential channel inhibitors |
WO2018162607A1 (en) | 2017-03-07 | 2018-09-13 | F. Hoffmann-La Roche Ag | Oxadiazole transient receptor potential channel inhibitors |
US10710994B2 (en) * | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
-
2019
- 2019-03-15 US US16/355,352 patent/US10710994B2/en active Active
- 2019-03-18 CR CR20200413A patent/CR20200413A/es unknown
- 2019-03-18 WO PCT/US2019/022659 patent/WO2019182925A1/en unknown
- 2019-03-18 SG SG11202009136RA patent/SG11202009136RA/en unknown
- 2019-03-18 CA CA3091486A patent/CA3091486A1/en active Pending
- 2019-03-18 MX MX2020009657A patent/MX2020009657A/es unknown
- 2019-03-18 JP JP2020550612A patent/JP7095106B2/ja active Active
- 2019-03-18 KR KR1020237015886A patent/KR20230070333A/ko not_active Application Discontinuation
- 2019-03-18 MA MA052077A patent/MA52077A/fr unknown
- 2019-03-18 PE PE2020001418A patent/PE20210660A1/es unknown
- 2019-03-18 CN CN201980020491.7A patent/CN111867585A/zh active Pending
- 2019-03-18 AU AU2019237992A patent/AU2019237992A1/en active Pending
- 2019-03-18 TW TW108109093A patent/TWI829676B/zh active
- 2019-03-18 EP EP19714073.4A patent/EP3768260A1/en active Pending
- 2019-03-18 IL IL276654A patent/IL276654B2/en unknown
- 2019-03-18 BR BR112020018983-9A patent/BR112020018983A2/pt unknown
- 2019-03-18 KR KR1020207029785A patent/KR102533094B1/ko active IP Right Grant
-
2020
- 2020-06-16 US US16/903,020 patent/US11655245B2/en active Active
- 2020-09-16 CL CL2020002399A patent/CL2020002399A1/es unknown
- 2020-09-18 PH PH12020551501A patent/PH12020551501A1/en unknown
- 2020-09-24 CO CONC2020/0011852A patent/CO2020011852A2/es unknown
-
2022
- 2022-06-22 JP JP2022100252A patent/JP2022126779A/ja active Pending
- 2022-08-02 US US17/816,855 patent/US20230121700A1/en active Pending
-
2023
- 2023-07-30 IL IL304835A patent/IL304835A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CR20200413A (es) | 2020-11-23 |
US11655245B2 (en) | 2023-05-23 |
RU2020133430A (ru) | 2022-04-19 |
KR20230070333A (ko) | 2023-05-22 |
TWI829676B (zh) | 2024-01-21 |
EP3768260A1 (en) | 2021-01-27 |
KR20200133358A (ko) | 2020-11-27 |
IL276654A (en) | 2020-09-30 |
US20200308161A1 (en) | 2020-10-01 |
CL2020002399A1 (es) | 2020-12-18 |
CO2020011852A2 (es) | 2020-10-20 |
IL304835A (en) | 2023-09-01 |
MX2020009657A (es) | 2020-10-08 |
TW202003510A (zh) | 2020-01-16 |
IL276654B2 (en) | 2024-01-01 |
BR112020018983A2 (pt) | 2020-12-29 |
KR102533094B1 (ko) | 2023-05-16 |
JP7095106B2 (ja) | 2022-07-04 |
MA52077A (fr) | 2021-01-27 |
WO2019182925A1 (en) | 2019-09-26 |
US10710994B2 (en) | 2020-07-14 |
CA3091486A1 (en) | 2019-09-26 |
JP2021518388A (ja) | 2021-08-02 |
SG11202009136RA (en) | 2020-10-29 |
CN111867585A (zh) | 2020-10-30 |
JP2022126779A (ja) | 2022-08-30 |
US20230121700A1 (en) | 2023-04-20 |
AU2019237992A1 (en) | 2020-09-03 |
IL276654B1 (en) | 2023-09-01 |
PH12020551501A1 (en) | 2021-09-06 |
US20190284179A1 (en) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210660A1 (es) | Inhibidores de canal de potencial de receptor transitorio de oxadiazol | |
RU2395506C2 (ru) | Антагонисты рецептора хемокина | |
RU2016146365A (ru) | Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b | |
PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion | |
JP6500010B2 (ja) | 新規ピリジン誘導体 | |
PE20210655A1 (es) | Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa | |
JP5903499B2 (ja) | ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体 | |
AR110403A1 (es) | Fungicidas de oxadiazoles | |
PE20131377A1 (es) | Triazina-oxadiazoles | |
PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
PE20191757A1 (es) | Compuestos heterociclicos utiles como inhibidores dobles de atx/ca | |
AR042469A1 (es) | Derivados de triazol como inhibidores de 11- beta - hidroxiesteroide deshidrogenasa - 1 | |
AR068496A1 (es) | Piperidinas sustituidas, una composicion farmaceutica que las comprende y su uso para el tratamiento de enfermedades mediadas por la modulacion de la actividad de gpr119. | |
PE20121474A1 (es) | Nuevos compuestos de espiropiperidina | |
PE20140302A1 (es) | Inhibidores del virus de la hepatitis c | |
PE20212247A1 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos | |
PE20080538A1 (es) | Derivado heterociclico fusionado y su uso | |
PE20110367A1 (es) | DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2 | |
PE20081228A1 (es) | Compuesto heteromonociclico | |
JP2007502774A (ja) | 有糸分裂キネシン阻害薬 | |
AR073688A1 (es) | Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras. | |
PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
PE20161363A1 (es) | Moduladores del receptor acoplado a la proteina g40 (gpr40) de pirrolidina para el tratamiento de enfermedades como la diabetes |